MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Ardelyx Inc

Închisă

SectorSănătate

4.73 -3.27

Rezumat

Modificarea prețului

24h

Curent

Minim

4.52

Maxim

4.87

Indicatori cheie

By Trading Economics

Venit

5.5M

4.6M

Vânzări

18M

116M

EPS

0.02

Marjă de profit

4

Angajați

395

EBITDA

6M

11M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+136.12% upside

Dividende

By Dow Jones

Următoarele câștiguri

1 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-93M

1.2B

Deschiderea anterioară

8

Închiderea anterioară

4.73

Sentimentul știrilor

By Acuity

22%

78%

55 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ardelyx Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 ian. 2025, 23:40 UTC

Principalele dinamici ale pieței

Ardelyx Shares Rise as Chairman Mott Increases Stake in Company

Comparație

Modificare preț

Ardelyx Inc Așteptări

Obiectiv de preț

By TipRanks

136.12% sus

Prognoză pe 12 luni

Medie 11.31 USD  136.12%

Maxim 15 USD

Minim 5.5 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArdelyx Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

6

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.745 / 5.14Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

55 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.